Susan Abughosh to Cost-Benefit Analysis
This is a "connection" page, showing publications Susan Abughosh has written about Cost-Benefit Analysis.
Connection Strength
1.117
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
Score: 0.940
-
Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug; 21(4):829-836.
Score: 0.177